Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：6

作者：

Balmanoukian, A. S. ^{[1
]}

Rizvi, N. A. ^{[2
]}

Garon, E. B. ^{[3
]}

Patnaik, A. ^{[4
]}

Gandhi, L. ^{[5
]}

Leighl, N. B. ^{[6
]}

Goldman, J. W. ^{[7
]}

Eder, J. P. ^{[8
]}

Johnson, E. A. ^{[9
]}

Blumenschein, G. R. ^{[10
]}

Gubens, M. A. ^{[11
]}

Papadopoulos, K. P. ^{[4
]}

Lubiniecki, G. M. ^{[12
]}

Zhang, J. ^{[13
]}

Niewood, M. ^{[12
]}

Emancipator, K. ^{[14
]}

Dolled-Filhart, M. ^{[15
]}

Hanson, M. E. ^{[16
]}

Hui, R. ^{[17
]}

机构：

[1] Angeles Clin & Res Inst, Los Angeles, CA USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[4] South Texas Accelerated Res Therapeut, San Antonio, TX USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Princess Margaret Canc Ctr UHN, Toronto, ON, Canada

[7] Univ Calif Los Angeles, Santa Monica, CA USA

[8] Yale Univ, New Haven, CT USA

[9] Mayo Clin Florida, Jacksonville, FL USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Univ Calif San Francisco, San Francisco, CA 94143 USA

[12] Merck & Co Inc, Whitehouse Stn, NJ USA

[13] Merck & Co Inc, Gwynedd, PA USA

[14] Merck Res Labs, Rahway, NJ USA

[15] Merck & Co Inc, Rahway, NJ 07065 USA

[16] Merck & Co Inc, Rahway, NJ 07065 USA

[17] Westmead Hosp, Sydney, NSW, Australia

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2014年 / 90卷

关键词：

D O I：

10.1016/j.ijrobp.2014.08.023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S1 / S2

页数：2

共 50 条

[21] Clinical implications of telomerase activity in non-small cell lung cancer (NSCLC)
Ramírez, JL
Sancho, E
Núñez, L
Sánchez, JJ
Balañá, C
López, P
Martín, C
Monzó, M
Rosell, R
EUROPEAN JOURNAL OF CANCER, 1999, 35 : S39 - S39
[22] Clinical implications of telomerase activity in non-small cell lung cancer (NSCLC)
Pifarre, A
Monzo, M
Martin, C
Sanchez, JJ
Barnadas, A
Rosell, R
ANNALS OF ONCOLOGY, 1998, 9 : 92 - 92
[23] A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer
Herbst, Roy S.
Gurpide, Alfonso
Surmont, Veerle
Kim, Dong-Wan
Waqar, Salem Naheed
Herder, Judith
Lee, Dae Ho
Carcereny, Enric
Reguart, Naomi
Wallmark, John M.
Ramalingam, Suresh S.
Langer, Corey J.
Lubiniecki, Gregory M.
Knowles, James
Zhou, Honghong
Hanson, Mary Elizabeth
Baas, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[24] Clinical validation and utility of InVision ctDNA in advanced non-small cell lung cancer (NSCLC) patients
Remon, J.
Mezquita, L.
Planchard, D.
Jovelet, C.
Lacroix, L.
Rouleau, E.
Howarth, K.
Plagnol, V.
Morris, C.
Green, E.
Le Pechoux, C.
Caramella, C.
Adam, J.
Besse, B.
ANNALS OF ONCOLOGY, 2018, 29
[25] Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001)
Garon, Edward B.
Rizvi, Naiyer
Hui, Rina
Leighl, Natasha B.
Balmanoukian, Ani S.
Eder, Joseph P.
Patnaik, Amita
Aggarwal, Charu
Gubens, Matthew A.
Horn, Leora
Carcereny, Enric
Ahn, Myung-Ju
Felip, Enriqueta
Lee, Jong-Seok
Zhang, Jin
Rangwala, Reshma A.
Lubiniecki, Gregory M.
Roach, Charlotte M.
Emancipator, Kenneth
Gandhi, Leena
CANCER RESEARCH, 2015, 75
[26] Evaluation of clinical and molecular changes in advanced non-small cell lung cancer(NSCLC)
Pilnik, N
Di Rienzo, J
Spitale, L
Grasso, R
Henin, A
Caminos, S
LUNG CANCER: CURRENT TOPICS, 2001, : 65 - 70
[27] Clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475) in KEYNOTE-012
Muro, Kei
ANNALS OF ONCOLOGY, 2015, 26 : 12 - 12
[28] Phase I Trial of MK-3475 and Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer
Welsh, J. W.
Heymach, J.
Cushman, T. R.
Hess, K.
Shroff, G.
Tang, C.
Skoulidis, F.
Jeter, M. D.
Nguyen, Q. N.
Chang, J. Y.
Papadimitrakopoulou, V.
Gomez, D. R.
Sharma, P.
Allison, J. P.
Raju, U.
Shaaban, S.
Byers, L.
Glisson, B. S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E727 - E727
[29] Personalized Therapy of Non-small Cell Lung Cancer (NSCLC)
Gadgeel, Shirish M.
LUNG CANCER AND PERSONALIZED MEDICINE: NOVEL THERAPIES AND CLINICAL MANAGEMENT, 2016, 890 : 203 - 222
[30] Induction therapy for non-small cell lung cancer (NSCLC)
Nakamura, H
Furukawa, K
Ikeda, N
Shibuya, H
Tanaka, K
Okunaka, T
Hirano, T
Sakai, M
Saito, M
Konaka, C
Kato, H
XXX WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS, VOLS 1-2, 1996, : 1029 - 1033

← 1 2 3 4 5 →